News Analysis: Hainan free trade port moves to forefront of China's opening-up drive
"This place is top-notch. They cater to so many aspects of wellness, not just physical, but mental too," she told Xinhua during her stay in the Boao Lecheng International Medical Tourism Pilot Zone, which hosts over 30 top-tier domestic and international medical institutions.
Thanks to special policy support, the pilot zone has introduced 485 cutting-edge medicines and medical devices that are licensed abroad but not yet available in the domestic market. The policy has benefited more than 130,000 patients, including individuals like Yau.
Her four-day experience -- blending advanced health screenings, traditional therapies, tea ceremonies, and cultural immersion -- offers much more than just a chance to relax. It showcases a tangible outcome of a key move in China's opening-up strategy: the transformation of Hainan into a Free Trade Port (FTP).
As the Hainan FTP is set to begin independent customs operations by the end of the year, it is poised to become not only a tourist haven but also a pivotal gateway for China's opening-up drive.
FRONTIER FOR FREE-FLOWING FACTORS
A central component of this transformation is the Lecheng medical tourism pilot zone. A total of 25 medical tourism routes have been rolled out to cater to a wide range of needs, including traditional Chinese medicine, chronic disease care, luxury diagnostics and cosmetic rehab, garnering popularity among visitors from countries such as Indonesia, Russia, Spain, and beyond.
In 2024, the medical special zone attracted over 410,000 medical visitors, up 36.76 percent year on year.
Lecheng is only one part of Hainan's wider push for opening up. Beyond the medical sector, the province has been fast-tracking foreign access across sectors ranging from finance and education to communication and high-tech industries, as China aims to build an FTP with global top-tier trade standards.
Hainan, supported by the country's vast domestic market and its strategic positioning, stands as a vital hub that connects the world's second-largest economy with global markets.
The FTP is gearing up to be "a pivotal gateway leading China's new era of opening-up," said Chi Fulin, head of the China Institute for Reform and Development.
With independent customs operations imminent, the FTP's policy framework, underpinned by features like zero tariffs, low tax rates, simplified tax systems and facilitated factor flows, has taken shape.
For firms in Lecheng, a zero-tariff policy on medical imports has saved nearly 8.2 million yuan (about 1.14 million U.S. dollars) in duties since December 2024.
The start of independent customs operations will represent a concrete step toward building a major gateway for China's high-level opening-up, Chi said.
INSTITUTIONAL OPENING-UP LURING FOREIGN CAPITAL
As Hainan FTP has prioritized institutional integration and coordination across trade, finance and regulatory systems, experts believe this will create a powerful driving force for the development of the FTP and contribute to China's high-standard opening up strategy.
Official data showed that so far, the province has rolled out a total of 158 institutional innovation cases. These reform measures include technology-empowered public tendering, one-stop business licensing, and a specialized IP zone to support the seed industry.
Hainan FTP serves not only as a testing ground for free-flowing goods, services and data, but as a frontier for the innovation of regulations and mechanisms, said Zhou Xiaochuan, vice chairman of the Boao Forum for Asia (BFA).
With its optimized business environment, Hainan has emerged as a premier foreign investment destination, ranking among China's top performers. In 2024, the number of foreign-invested enterprises in Hainan rose 19.2 percent year on year, while its foreign direct investment volume climbed to the tenth spot nationally.
To date, Hainan has attracted investment from 158 countries and regions, while its economic openness ratio -- the ratio of total trade to GDP -- more than doubled from 17.3 percent in 2018 to 35 percent in 2024.
High-profile events held in the province like the BFA, a premier platform advocating openness and multilateral cooperation, and the China International Consumer Products Expo, the largest consumer expo in the Asia-Pacific region, offer global investors dynamic gateways to observe the country's evolving openness agenda.
DFS, the travel retail company of the luxury goods conglomerate LVMH, in 2024 sealed its largest single investment in 60 years to launch a landmark complex in Yalong Bay of Sanya, the well-known tropical resort city in Hainan. The project will merge luxury retail, hotels and entertainment, with the goal of building a top destination for luxury shopping and tourism.
"Hainan FTP embodies China's commitment to high-standard openness," said Nancy Liu, president of DFS China.
China's special economic zones, like Hainan FTP and the 21 pilot free trade zones, serve as pivotal engines for industrial transformation and opening up, Chi noted, highlighting their role as "growth accelerators for both regional and global economies."
When the independent customs operations begin, Hainan FTP will create key opportunities for international enterprises to access China's domestic market more efficiently, and play a greater role in enhancing market connectivity with global markets through service trade-focused regulatory alignment, he added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
an hour ago
- National Post
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. ('IPA', 'Company', 'we' or 'us') (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Article content Financial Highlights: Article content Article content Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0 million Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24 BioStrand segment grew over 180% in Fiscal year 2025 and had gross margins approaching 90% BioStrand currently represents over 5% of total annual revenue this year, up from less than 2% in Fiscal Year 2024 Article content : Article content The Company's LENS ai ™ platform demonstrated that it's in silico epitope mapping achieves results on previously unseen antibody–antigen complexes with results that are on par with gold-standard X-ray crystallography—yet delivering structural insights in hours instead of weeks. An important breakthrough using the Company's HYFT®-powered LENS ai platform, as it identified a highly conserved epitope across all four dengue virus serotypes, a key milestone toward developing a potential universal dengue vaccine. Subsequently announced in silico data supporting the vaccine candidate's safety and its ability to activate a balanced immune response. IPA's AI-designed GLP-1 peptides outperformed or matched semaglutide in independent receptor activation studies, further validating the Company's HYFT-driven LENS ai platform. Entered a strategic USD $8–10 million partnership with a publicly traded biotechnology company focused on the discovery and development of antibody-drug conjugates and bispecific antibodies for potential oncology therapeutics. Realigned internal R&D strategy to focus on launching an AI-powered therapeutic pipeline, reinforcing IPA's shift toward a bio-native AI drug discovery model. ImmunoPrecise subsidiary signed material transfer agreement with Biotheus (now BioNTech), for the transfer and evaluation of antibody assets for bispecific tumor-targeting. Successfully engineered antibodies in silico to a challenging tumor target using LENS ai, advancing IPA's vision for accessible, next-generation therapeutics. Appointed industry veteran Jon Lieber to its Board of Directors, bringing over 30 years of strategic leadership across biotech, capital markets, and public company governance, further strengthening IPA's financial oversight and commercial execution. Named Jeff Fried, a recognized healthcare data visionary, to its Advisory Board. Fried has played a key role in advancing IPA's AI platform capabilities, particularly the integration of vector search to support large-scale, AI-driven discovery within LENS ai ecosystem. Regained compliance with Nasdaq minimum bid price requirement, reflecting strengthened investor confidence and continued alignment with strategic listing standards. Article content 'Fiscal 2025 was a record-setting year for IPA across multiple dimensions,' said Dr. Jennifer Bath, ImmunoPrecise Antibodies CEO. 'We delivered strong annual and record fourth quarter revenues, significantly improved gross margins, and achieved one of our strongest adjusted EBITDA performances in the Company's history, with a loss of only $316,000. This reflects our continued progress toward profitability while accelerating innovation through our HYFT-powered LENS ai platform. Our BioStrand segment alone grew by more than 180% in Fiscal 2025, highlighting the strength of our AI-driven pipeline. These results underscore the growing commercial validation of our technology, our strategic collaborations, and our ability to deliver real-world impact through next-generation antibody discovery and therapeutic design.' Article content 'As we look ahead to the next fiscal year, we are well-positioned to build on our momentum. We are poised to refocus our business on AI-based product development utilizing our LENS ai platform, powered by our patented HYFT technology. We anticipate the near-term completion of the previously announced divestiture of our Dutch subsidiary, as part of our continued focus on streamlining operations and aligning resources with strategic priorities. Together, these strategic steps will sharpen our focus, strengthen our core capabilities, and set the stage for an even brighter future for IPA,' concluded Dr. Bath. Article content Fourth Quarter 2025 Financial Results Article content Revenue for the three months ended April 30, 2025, was $7.0 million, representing an 8% increase compared to $6.5 million for the same period in 2024. Article content Gross profit for the three months ended April 30, 2025, was $4.5 million, up from $3.1 million in the same period last year. Gross margin for FY25 rose sharply to 64%, compared to 48% for FY24. This improvement was driven, in part, by a greater contribution from high-margin BioStrand revenues. Article content Research and development ('R&D') expenses totaled $1.1 million, down from $1.3 million in the prior-year quarter, due to reallocating project-related R&D efforts to cost of sales for clients. Article content Sales and marketing expenses increased to $1.0 million, compared to $0.9 million in the same period last year, due to an increase in digital campaign expenses. Article content General and administrative expenses declined to $3.7 million from $4.1 million, driven by ongoing cost control efforts. Article content Operating loss, excluding amortization and non-recurring charges, improved significantly to $1.4 million, compared to $3.2 million in the fourth quarter of Fiscal Year 2024. Article content Net loss narrowed to $2.2 million, a marked improvement from a net loss of $17.6 million in the same quarter last year, which included a $15 million non-cash impairment charge related to BioStrand's goodwill and intangible assets. Article content Adjusted EBITDA loss improved to $0.3 million, compared to a loss of $1.7 million in the fourth quarter of Fiscal Year 2024, reflecting improved gross profits and enhanced operating efficiency. Article content Full Year 2025 Financial Results Article content Revenue for Fiscal Year 2025 was $24.5 million, up slightly (without rounding) from $24.5 million in Fiscal Year 2024. Article content Gross Profit for Fiscal Year 2025 was $13.5 million, a 12.4% increase compared to $12.1 million in Fiscal Year 2024. Gross margin expanded by 600 basis points to 55%, up from 49% in the prior year. This margin improvement was driven by a greater revenue contribution from the high-margin BioStrand segment, coupled with an increased focus on cost efficiencies. Article content Research and development expenses were $4.9 million in Fiscal Year 2025, up from $4.0 million in Fiscal Year 2024, reflecting increased investment in R&D activities within the BioStrand segment. Article content Sales and marketing expenses were $4.3 million in Fiscal Year 2025, compared to $3.5 million in Fiscal Year 2024, reflecting increased spending on advertising related to digital campaign expenses. Article content General and administrative expenses totaled $14.7 million in Fiscal Year 2025, down from $15.6 million in Fiscal Year 2024, reflecting the Company's continued focus on operational efficiency and cost discipline. Article content Operating loss in Fiscal Year 2025, excluding amortization and non-recurring charges, improved to $10.4 million, compared to $11.1 million in Fiscal Year 2024. Article content Net loss in Fiscal Year 2025 was $30.2 million, or $(0.91) per share on a basic and diluted basis, compared to a net loss of $26.1 million or $(1.02) on a basic and diluted basis in Fiscal Year 2024. Article content Total cash, cash equivalents, and marketable securities, including restricted cash, were $10.8 million as of April 30, 2025. Article content Three Months Ended April 30, Year Ended April 30, (in thousands) 2025 $ 2024 $ 2025 $ 2024 $ Net loss (2,161 ) (17,610 ) (30,234 ) (26,115 ) Income taxes 261 (1,214 ) (4,033 ) (2,588 ) Amortization and depreciation 913 1,579 5,119 5,735 Accretion 2 4 10 19 Asset impairment charge — 15,031 21,184 15,031 Foreign exchange realized gain (loss) (33 ) 18 (5 ) 142 Interest expense 209 323 948 849 Interest and other income (3 ) 3 283 (23 ) Unrealized foreign exchange loss (gain) 443 (65 ) 594 (86 ) Share-based expense 53 237 445 1,535 Adjusted EBITDA (316 ) (1,694 ) (5,689 ) (5,501 ) Article content *All financial figures are in Canadian Dollars (CAD) unless otherwise stated. Article content Conference Call and Webcast Details Article content The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Friday, July 29, 2025, at 10:30AM ET. Article content The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at Article content ***Participant Dial-In Details*** Article content Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name. Article content USA / International Toll +1 (646) 307-1963 USA – Toll-Free (800) 715-9871 Canada – Toll-Free (800) 715-9871 Article content ***Webcast Details*** Article content Attendee URL: Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. Article content Anyone listening to the call is encouraged to read the company's periodic reports available on the company's profile at and including the discussion of risk factors and historical results of operations and financial condition in those reports. Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise Antibodies Ltd. is an AI-driven biotherapeutic research, technology and scientifically robust life science company that discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures and innovative approaches to antibody discovery, development, and production. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). Article content For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. These statements reflect the Company's expectations, plans, projections, and beliefs regarding future events or performance. Words such as 'expects,' 'anticipates,' 'intends,' 'believes,' 'plans,' 'potential,' 'will,' 'may,' 'continue,' and variations thereof are intended to identify forward-looking statements. Article content Forward-looking statements in this release include, but are not limited to, statements related to the Company's operational and financial outlook, the potential impact and continuity of strategic partnerships, including the recently announced commercial agreement and collaborations with cloud infrastructure providers, our projected growth in AI-driven revenues and margins, our ability to commercialize new technologies such as de novo antibody design and AI-designed GLP-1 therapeutics, future demand for our platform capabilities, ongoing strategic initiatives including business realignment and divestitures, and our ability to drive sustainable profitability. Article content The Company uses certain non-IFRS financial measures as supplemental indicators of its financial and operating performance. These non-IFRS financial measures are adjusted EBITDA and adjusted operating expenses. The Company believes these supplementary financial measures reflect the Company's ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in its business. These non-IFRS measures do not have any standardized meaning prescribed under IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Article content The Company defines adjusted EBITDA as operating earnings before taxes, amortization, depreciation, accretion, asset impairment charges, foreign exchange gain/loss, interest and other income and share-based compensation. Adjusted EBITDA is presented on a basis consistent with the Company's internal management reports. The Company discloses adjusted EBITDA to capture the profitability of its business before the impact of items not considered in management's evaluation of operating unit performance. The most directly comparable IFRS measure to adjusted EBITDA is net loss. Article content These statements are based on management's current expectations and assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. These include, but are not limited to: execution risks related to strategic partnerships, delays or failures in technology development or commercialization, market adoption of AI-based drug discovery tools, fluctuations in financial markets, general economic conditions, and risks related to funding requirements and liquidity. Article content The Company cautions readers not to place undue reliance on these forward-looking statements. All such statements are made as of the date of this release and, unless required by law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. Article content IMMUNOPRECISE ANTIBODIES LTD. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited – Expressed in Canadian dollars) (in thousands) April 30, 2025 $ April 30, 2024 $ ASSETS Current assets Cash 10,665 3,459 Amounts receivable, net 4,115 3,790 Tax receivable 143 414 Inventory 2,095 2,139 Unbilled revenue 548 277 Prepaid expenses 1,188 1,408 18,754 11,487 Restricted cash 126 86 Deposit on equipment 502 475 Property and equipment 15,762 16,696 Intangible assets 1,067 23,557 Goodwill 8,230 7,687 Total assets 44,441 59,988 LIABILITIES Current liabilities Accounts payable and accrued liabilities 5,283 4,372 Deferred revenue 1,090 1,352 Tax payable 475 553 Leases 1,850 1,563 Deferred acquisition payments 314 284 9,012 8,124 Leases 11,553 12,118 Deferred income tax liability 250 4,068 Total liabilities 20,815 24,310 SHAREHOLDERS' EQUITY Share capital 136,371 119,773 Contributed surplus 12,833 12,388 Accumulated other comprehensive income 3,216 2,077 Accumulated deficit (128,794 ) (98,560 ) 23,626 35,678 Total liabilities and shareholders' equity 44,441 59,988 Article content IMMUNOPRECISE ANTIBODIES LTD. CONSOLIDATED STATEMENTS OF CASH FLOWS For the year ended April 30, 2025 and 2024 (Unaudited – Expressed in Canadian dollars) (in thousands) 2025 $ 2024 $ Operating activities: Net loss for the period (30,234 ) (26,115 ) Items not affecting cash: Accretion 10 19 Amortization and depreciation 5,119 5,735 Asset impairment 21,184 15,031 Deferred income taxes (3,935 ) (1,773 ) Foreign exchange 622 15 Gain on investment (7 ) (2 ) Share-based expense 445 1,535 (6,796 ) (5,555 ) Changes in non-cash working capital related to operations: Amounts receivable (298 ) (601 ) Inventory 138 (102 ) Unbilled revenue (248 ) 360 Prepaid expenses 261 624 Accounts payable and accrued liabilities 827 983 Sales and income taxes payable and receivable 8 733 Deferred revenue (302 ) 374 Net cash used in operating activities (6,410 ) (3,184 ) Investing activities: Purchase of equipment (799 ) (1,397 ) Security deposit on leases — (141 ) Deferred acquisition payments — (146 ) Sale of QVQ Holdings BV shares — 121 Net cash used in investing activities (799 ) (1,563 ) Financing activities: Proceeds from share issuance, net of transaction costs 12,228 2,360 Proceeds from debenture 4,242 — Repayment of leases (1,577 ) (1,339 ) Net cash provided by financing activities 14,893 1,021 Increase (decrease) in cash during the period 7,684 (3,726 ) Foreign exchange (438 ) (1,095 ) Cash – beginning of the period 3,545 8,366 Cash – end of the period 10,791 3,545 Cash is comprised of: Cash 10,665 3,459 Restricted cash 126 86 10,791 3,545 Cash paid for interest — — Cash paid for income tax 2 — Article content Article content Article content Article content Article content Contacts Article content Article content Article content

Cision Canada
an hour ago
- Cision Canada
Stay Home Forever Inc. Appoints Dane Clarke as First President and Chief Operating Officer
Industry leader brings culture-driven approach to Ontario-based homecare provider Stay Home Forever Inc. as he steps into the newly created role of President and Chief Operating Officer. TORONTO, July 29, 2025 /CNW/ - Stay Home Forever Inc. ("SHF"), a leading provider of private homecare services across Ontario, today announced the appointment of Dane Clarke as the President and Chief Operating Officer, effective immediately. To support its next phase of growth, SHF has created this new role, appointing Dane to lead operations and strategy while driving immediate impact with a culture-driven mission. Dane brings over 20 years of executive experience in healthcare operations, workforce strategy, and organizational growth. He has held leadership roles at CBI Health Group, Sinai Health Systems, and WSIB, leading initiatives that improved outcomes and expanded service delivery. Dane also played a key role in driving system-level change and navigating crisis response for healthcare organizations, including Ontario Health Teams (OHTs), co-chairing the Home Care Table during the covid-19 pandemic, and a key contributor to various initiatives and stakeholder engagements with Ontario Health. He attended the Ivey School of Business, reinforcing his ability to lead transformational change and cross-sector healthcare initiatives. "We are thrilled to welcome Dane to the SHF family," said Saye Sathiyakumar, CEO of Stay Home Forever Inc. "His proven leadership, deep industry knowledge, and passion for compassionate care align perfectly with our values. Dane's vision and operational expertise will be instrumental as we continue to scale our services and innovate in the homecare sector." "Joining Stay Home Forever is both a professional and personal calling," said Dane. "I look forward to working closely with Saye and the SHF team to strengthen our foundation, expand our services, and meet the growing need for culturally responsive care in Ontario." Dane's appointment reflects Stay Home Forever's identity as a proudly minority-owned company. As a second-generation Canadian, his personal experiences bring critical insight to a sector where much of the workforce shares similar backgrounds. His leadership helps ensure that the voices of underrepresented communities are reflected at every level of care. Stay Home Forever Inc. has earned a reputation for delivering personalized and client-centred care rooted in the belief that everyone deserves to live with dignity, comfort and connection. With Dane's leadership, SHF will continue to expand its tailored services and advance culturally responsive care for families across Ontario. About Stay Home Forever Inc. Founded in 2019, Stay Home Forever Inc. is a leading provider of private homecare services in Ontario. The company offers a comprehensive range of services - including personal care, companionship, nursing, and specialized support - all designed to promote independence and enhance quality of life. SHF is committed to delivering compassionate, reliable, and culturally appropriate care that meets the highest standards of excellence.


Edmonton Journal
an hour ago
- Edmonton Journal
Bath & Body Works refutes U.S. woman's lawsuit about exploding candle made at Canadian facility
Retailer Bath & Body Works is refuting a lawsuit filed by a woman who says she was severely burned by an exploding candle manufactured at a Canadian facility. Article content Renita Francois says she was lighting the candle from Bath & Body Works, with a scent called Sweater Weather, on Jan. 19, 2023 in her home on Long Island, New York. She leaned in to smell the candle when 'a sudden explosion erupted from the glass container, propelling molten wax and flames outward in every direction,' according to the lawsuit obtained by National Post. The explosion occurred 'within moments' of lighting the candle, the claim says. Article content Article content As well as Bath & Body Works, Francois is also suing Premier Candle Corporation, the Canadian candle producer, for 'negligence, failure to warn, product defect, breach of warranty,' which are related to 'a defective candle that exploded and caused severe burns and permanent disfigurement.' Article content Article content The suit, filed on July 4, alleges that both companies, 'despite knowing of prior explosions and safety risks related to their three-wick candles, failed to recall, redesign, or properly warn consumers about the risk of catastrophic injury.' Article content In an emailed statement to National Post, a spokesperson for Bath & Body Works denied the allegations. They said the explosion was due to misuse. Article content 'In millions of hours of testing we have never seen our candles explode. Based on third party testing it is evident that the candle involved in this incident was improperly burned and extinguished. Article content Article content 'Bath & Body Works stands by the safety of our product, and when used appropriately, our best-in-class safety and testing standards make our candles safe,' the statement said. Article content Article content It continued: 'All Bath & Body Works candles made by Premier in Canada are subject to the exact same quality standards, inspections, and rigorous testing as other candles manufactured and sold by Bath & Body Works in the United States.' Article content According to its website, Premier Candle Corporation says it has 'stringent procedures from incoming material inspections, batching confirmations, in process inspections, and many other quality checks up to the final pre-shipment inspection.' Article content Francois said she followed the instructions on the bottom of the candle and adhered to its safety warnings. The label says the candle should not be lit for more than four hours and that the wick should always be trimmed to a quarter of an inch before it is lit.